Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme
Publication
, Journal Article
Vredenburgh, J; Desjardins, A; Reardon, D
Published in: American Journal of Hematology/ Oncology
April 1, 2008
Duke Scholars
Published In
American Journal of Hematology/ Oncology
ISSN
1542-9520
Publication Date
April 1, 2008
Volume
7
Issue
4
Citation
APA
Chicago
ICMJE
MLA
NLM
Vredenburgh, J., Desjardins, A., & Reardon, D. (2008). Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme. American Journal of Hematology/ Oncology, 7(4).
Vredenburgh, J., A. Desjardins, and D. Reardon. “Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme.” American Journal of Hematology/ Oncology 7, no. 4 (April 1, 2008).
Vredenburgh J, Desjardins A, Reardon D. Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme. American Journal of Hematology/ Oncology. 2008 Apr 1;7(4).
Vredenburgh, J., et al. “Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme.” American Journal of Hematology/ Oncology, vol. 7, no. 4, Apr. 2008.
Vredenburgh J, Desjardins A, Reardon D. Irinotecan and bevacizumab for the treatment of recurrent glioblastoma multiforme. American Journal of Hematology/ Oncology. 2008 Apr 1;7(4).
Published In
American Journal of Hematology/ Oncology
ISSN
1542-9520
Publication Date
April 1, 2008
Volume
7
Issue
4